During the past decades, better understanding of relapsing-remitting multiple sclerosis
disease mechanisms have led to the development of several disease-modifying therapies …

The secondary progressive phase of multiple sclerosis (MS), which is characterised by a
steady accrual of fixed disability after an initial relapsing remitting course, is not clearly …

Multiple sclerosis is a chronic autoimmune disease of the central nervous system that results
in varying degrees of disability. Progressive multiple sclerosis, characterized by a steady …

Purpose of review Multiple sclerosis (MS) is an immune-mediated disorder that affects the
central nervous system (CNS), often first affecting people in early adulthood. Although most …

Methotrexate is used increasingly in low-dose regimes for a variety of conditions, particularly
rheumatoid arthritis. While certain adverse effects of low-dose methotrexate have been …

Despite the fact that majority of patients with multiple sclerosis (MS) have relapsing-remitting
disease, many transition to secondary progressive disease (SPMS) over time. This transition …

Oligodendrocytes and their precursors are critical glial facilitators of neurophysiology, which
is responsible for cognition and behavior. Devices that are used to interface with the brain …

Multiple sclerosis is a disease of the central nervous system, resulting in the demyelination
of neurons, causing mild to severe symptoms. Several anti-inflammatory treatments now …

Research into therapy for multiple sclerosis (MS) is occurring at a rapid pace, and current
treatment options approved by the FDA specifically target the inflammatory phase of MS …

BACKGROUND: Methotrexate, a toxic antimetabolite that limits cellular reproduction by
acting as an antagonist to folic acid, has been used to control autoimmune disease with …